[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fiE-b65XR3iBSLRwb3_n3DLE-6aWaixCObHmxSUdMoeA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":83,"rows":90},"National Cancer Centre, Singapore",[4],112,false,33,7,50382,14,51,[14,17,19,22,24,27,29,32],{"name":15,"count":16},"Breast Cancer",9,{"name":18,"count":16},"Hepatocellular Carcinoma",{"name":20,"count":21},"Head and Neck Cancer",6,{"name":23,"count":21},"Colorectal Cancer",{"name":25,"count":26},"Nasopharyngeal Carcinoma",5,{"name":28,"count":26},"Non-Small Cell Lung Cancer",{"name":30,"count":31},"Non-small Cell Lung Cancer",4,{"name":33,"count":31},"Cancer",[35,40,45,49,54,59,63,68,73,78],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05929885","Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients","2026-02-28","Low Dose OXIRI",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05773092","A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC","2026-03-31","Oral S-1 + Oral Osimertinib",{"nctId":46,"briefTitle":47,"date":43,"intervention":48},"NCT04027647","Phase 2 Study of Dacomitinib in NSCLC","Dacomitinib",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT05377034","Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients","2026-07-25","SIRT-Y90 with Atezolizumab + Bevacizumab",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06587295","Intramuscular ACM-CpG Monotherapy in Patients With Advanced\u002FMetastatic Solid Tumors With Prior Response to Immunotherapy Alone or in Combination With Chemotherapy","2026-12","Intramuscular ACM-CpG Monotherapy",{"nctId":60,"briefTitle":61,"date":57,"intervention":62},"NCT04912765","Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC","Neoantigen Dendritic Cell Vaccine",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT05286437","Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole","2026-12-31","Oral Lenvatinib + Intravenous (IV) Pembrolizumab + Oral Letrozole",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT05516628","Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma","2027-03","Adjuvant Atezolizumab-Bevacizumab Therapy",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT04946968","Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers","2027-04","Oral Dacomitinib",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT06160843","Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma","2028-01","Pembrolizumab IV infusion Q3W, with daily oral Olaparib.",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,173,198,219,247,270,293,311,330,353,374,399,417,438,459,515,550,589,619,647,671,689,730,756,786,808,844,866,902,924,942,960,984,1008,1032,1050,1068,1086,1104,1128,1152,1170,1188,1211,1229,1247,1265,1283,1301,1319,1345,1369,1387,1412,1437,1455,1477,1503,1521,1539,1557,1581,1599,1624,1642,1667,1685,1711,1736,1760,1786,1804,1829,1855,1882,1900,1929,1947,1965,1983,2001,2027,2052,2070,2093],{"intervention":92,"totalTrials":21,"cells":93},"Nivolumab",{"EARLY_PHASE1":94,"PHASE1":97,"PHASE2":99,"PHASE3":167,"PHASE4":169,"NA":171},{"trials":95,"activeCount":96},[],0,{"trials":98,"activeCount":96},[],{"trials":100,"activeCount":166,"soonestReadout":57},[101,112,124,134,143,155],{"nctId":102,"briefTitle":103,"status":104,"phases":105,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":109,"interventions":110},"NCT03091491","Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer","TERMINATED",[86],"2019-11-18","2017-04-07",31,[28],[111,92],"Ipilimumab",{"nctId":113,"briefTitle":114,"status":115,"phases":116,"primaryCompletion":117,"completion":117,"start":118,"enrollment":108,"conditions":119,"interventions":121},"NCT04620954","Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin","UNKNOWN",[85,86],"2022-07","2020-10-07",[120],"Epithelial Ovarian Cancer",[122,92,123],"Oregovomab","Chemotherapy",{"nctId":125,"briefTitle":126,"status":104,"phases":127,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":133},"NCT03100006","Phase Ib\u002FIIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin",[85,86],"2019-06-07","2020-04-17","2017-02-22",13,[120],[92,122],{"nctId":135,"briefTitle":136,"status":115,"phases":137,"primaryCompletion":138,"completion":138,"start":139,"enrollment":140,"conditions":141,"interventions":142},"NCT03097939","Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma",[86],"2024-12-31","2017-03-31",113,[25],[111,92],{"nctId":144,"briefTitle":145,"status":146,"phases":147,"primaryCompletion":148,"completion":149,"start":150,"enrollment":151,"conditions":152,"interventions":154},"NCT03033446","Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma","COMPLETED",[86],"2019-08-31","2023-04-26","2016-12-20",40,[153],"HepatoCellular Carcinoma",[92],{"nctId":60,"briefTitle":61,"status":156,"phases":157,"primaryCompletion":57,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":165},"RECRUITING",[86],"2027-06","2021-04-15",60,[18,162,23,163,164],"Hepatocellular Cancer","Colorectal Carcinoma","Liver Metastases",[62,92],1,{"trials":168,"activeCount":96},[],{"trials":170,"activeCount":96},[],{"trials":172,"activeCount":96},[],{"intervention":174,"totalTrials":166,"cells":175},"CCRT with Maintenance Tislelizumab and Metronomic Capecitabine",{"EARLY_PHASE1":176,"PHASE1":178,"PHASE2":180,"PHASE3":192,"PHASE4":194,"NA":196},{"trials":177,"activeCount":96},[],{"trials":179,"activeCount":96},[],{"trials":181,"activeCount":166,"soonestReadout":186},[182],{"nctId":183,"briefTitle":184,"status":156,"phases":185,"primaryCompletion":186,"completion":187,"start":188,"enrollment":189,"conditions":190,"interventions":191},"NCT06093061","Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma",[86],"2028-10","2029-10","2024-07-03",53,[25],[174],{"trials":193,"activeCount":96},[],{"trials":195,"activeCount":96},[],{"trials":197,"activeCount":96},[],{"intervention":39,"totalTrials":166,"cells":199},{"EARLY_PHASE1":200,"PHASE1":202,"PHASE2":204,"PHASE3":213,"PHASE4":215,"NA":217},{"trials":201,"activeCount":96},[],{"trials":203,"activeCount":96},[],{"trials":205,"activeCount":166,"soonestReadout":38},[206],{"nctId":36,"briefTitle":37,"status":156,"phases":207,"primaryCompletion":38,"completion":38,"start":208,"enrollment":209,"conditions":210,"interventions":212},[86],"2023-08-30",50,[211],"Metastatic Pancreatic Cancer",[39],{"trials":214,"activeCount":96},[],{"trials":216,"activeCount":96},[],{"trials":218,"activeCount":96},[],{"intervention":220,"totalTrials":166,"cells":221},"Sacituzumab Tirumotecan",{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":241,"PHASE4":243,"NA":245},{"trials":223,"activeCount":96},[],{"trials":225,"activeCount":96},[],{"trials":227,"activeCount":166,"soonestReadout":233},[228],{"nctId":229,"briefTitle":230,"status":231,"phases":232,"primaryCompletion":233,"completion":233,"start":234,"enrollment":235,"conditions":236,"interventions":240},"NCT07521670","Sacituzumab Tirumotecan in Recurrent\u002FMetastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)","NOT_YET_RECRUITING",[86],"2028-10-31","2026-05",68,[237,238,239],"Recurrent Adenoid Cystic Carcinoma","Adenoid Cystic Carcinoma Metastatic","Papillary Thyroid Carcinoma",[220],{"trials":242,"activeCount":96},[],{"trials":244,"activeCount":96},[],{"trials":246,"activeCount":96},[],{"intervention":44,"totalTrials":166,"cells":248},{"EARLY_PHASE1":249,"PHASE1":251,"PHASE2":253,"PHASE3":264,"PHASE4":266,"NA":268},{"trials":250,"activeCount":96},[],{"trials":252,"activeCount":96},[],{"trials":254,"activeCount":166,"soonestReadout":43},[255],{"nctId":41,"briefTitle":42,"status":256,"phases":257,"primaryCompletion":43,"completion":258,"start":259,"enrollment":260,"conditions":261,"interventions":263},"ACTIVE_NOT_RECRUITING",[86],"2028-03-31","2023-08-01",30,[262],"NSCLC",[44],{"trials":265,"activeCount":96},[],{"trials":267,"activeCount":96},[],{"trials":269,"activeCount":96},[],{"intervention":53,"totalTrials":166,"cells":271},{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":287,"PHASE4":289,"NA":291},{"trials":273,"activeCount":96},[],{"trials":275,"activeCount":96},[],{"trials":277,"activeCount":166,"soonestReadout":52},[278],{"nctId":50,"briefTitle":51,"status":156,"phases":279,"primaryCompletion":52,"completion":280,"start":281,"enrollment":282,"conditions":283,"interventions":285},[86],"2028-01-31","2022-10-26",100,[284],"Locally Advanced Hepatocellular Carcinoma",[53,286],"SIRT-Y90 with Placebo",{"trials":288,"activeCount":96},[],{"trials":290,"activeCount":96},[],{"trials":292,"activeCount":96},[],{"intervention":286,"totalTrials":166,"cells":294},{"EARLY_PHASE1":295,"PHASE1":297,"PHASE2":299,"PHASE3":305,"PHASE4":307,"NA":309},{"trials":296,"activeCount":96},[],{"trials":298,"activeCount":96},[],{"trials":300,"activeCount":166,"soonestReadout":52},[301],{"nctId":50,"briefTitle":51,"status":156,"phases":302,"primaryCompletion":52,"completion":280,"start":281,"enrollment":282,"conditions":303,"interventions":304},[86],[284],[53,286],{"trials":306,"activeCount":96},[],{"trials":308,"activeCount":96},[],{"trials":310,"activeCount":96},[],{"intervention":72,"totalTrials":166,"cells":312},{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":317,"PHASE3":324,"PHASE4":326,"NA":328},{"trials":314,"activeCount":96},[],{"trials":316,"activeCount":96},[],{"trials":318,"activeCount":166,"soonestReadout":71},[319],{"nctId":69,"briefTitle":70,"status":156,"phases":320,"primaryCompletion":71,"completion":71,"start":321,"enrollment":260,"conditions":322,"interventions":323},[86],"2023-02-28",[18],[72],{"trials":325,"activeCount":96},[],{"trials":327,"activeCount":96},[],{"trials":329,"activeCount":96},[],{"intervention":77,"totalTrials":166,"cells":331},{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":336,"PHASE3":347,"PHASE4":349,"NA":351},{"trials":333,"activeCount":96},[],{"trials":335,"activeCount":96},[],{"trials":337,"activeCount":166,"soonestReadout":76},[338],{"nctId":74,"briefTitle":75,"status":256,"phases":339,"primaryCompletion":76,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":346},[86],"2027-05","2021-08-24",24,[344,30,345],"Advanced Solid Tumours","Head and Neck Squamous Cell Carcinoma",[77],{"trials":348,"activeCount":96},[],{"trials":350,"activeCount":96},[],{"trials":352,"activeCount":96},[],{"intervention":67,"totalTrials":166,"cells":354},{"EARLY_PHASE1":355,"PHASE1":357,"PHASE2":359,"PHASE3":368,"PHASE4":370,"NA":372},{"trials":356,"activeCount":96},[],{"trials":358,"activeCount":96},[],{"trials":360,"activeCount":166,"soonestReadout":66},[361],{"nctId":64,"briefTitle":65,"status":156,"phases":362,"primaryCompletion":66,"completion":363,"start":364,"enrollment":151,"conditions":365,"interventions":367},[86],"2028-12-31","2023-02-15",[366],"Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer",[67],{"trials":369,"activeCount":96},[],{"trials":371,"activeCount":96},[],{"trials":373,"activeCount":96},[],{"intervention":48,"totalTrials":166,"cells":375},{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":393,"PHASE4":395,"NA":397},{"trials":377,"activeCount":96},[],{"trials":379,"activeCount":96},[],{"trials":381,"activeCount":166,"soonestReadout":43},[382],{"nctId":46,"briefTitle":47,"status":256,"phases":383,"primaryCompletion":43,"completion":43,"start":384,"enrollment":385,"conditions":386,"interventions":392},[86],"2019-09-11",118,[387,388,389,390,391],"NSCLC Stage IIIB","NSCLC Stage IIIC","NSCLC Stage IV","Recurrent NSCLC","EGFR Positive Non-Small Cell Lung Cancer",[48],{"trials":394,"activeCount":96},[],{"trials":396,"activeCount":96},[],{"trials":398,"activeCount":96},[],{"intervention":62,"totalTrials":166,"cells":400},{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":405,"PHASE3":411,"PHASE4":413,"NA":415},{"trials":402,"activeCount":96},[],{"trials":404,"activeCount":96},[],{"trials":406,"activeCount":166,"soonestReadout":57},[407],{"nctId":60,"briefTitle":61,"status":156,"phases":408,"primaryCompletion":57,"completion":158,"start":159,"enrollment":160,"conditions":409,"interventions":410},[86],[18,162,23,163,164],[62,92],{"trials":412,"activeCount":96},[],{"trials":414,"activeCount":96},[],{"trials":416,"activeCount":96},[],{"intervention":82,"totalTrials":166,"cells":418},{"EARLY_PHASE1":419,"PHASE1":421,"PHASE2":423,"PHASE3":432,"PHASE4":434,"NA":436},{"trials":420,"activeCount":96},[],{"trials":422,"activeCount":96},[],{"trials":424,"activeCount":166,"soonestReadout":81},[425],{"nctId":79,"briefTitle":80,"status":156,"phases":426,"primaryCompletion":81,"completion":81,"start":427,"enrollment":342,"conditions":428,"interventions":431},[86],"2024-07-01",[429,430],"Relapsed Peripheral T-Cell Lymphoma","Refractory Peripheral T-Cell Lymphoma",[82],{"trials":433,"activeCount":96},[],{"trials":435,"activeCount":96},[],{"trials":437,"activeCount":96},[],{"intervention":58,"totalTrials":166,"cells":439},{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":451,"PHASE3":453,"PHASE4":455,"NA":457},{"trials":441,"activeCount":96},[],{"trials":443,"activeCount":166,"soonestReadout":57},[444],{"nctId":55,"briefTitle":56,"status":156,"phases":445,"primaryCompletion":57,"completion":57,"start":446,"enrollment":151,"conditions":447,"interventions":450},[85],"2025-01-15",[448,449],"Advanced Solid Tumor","Metastatic Solid Tumor",[58,58],{"trials":452,"activeCount":96},[],{"trials":454,"activeCount":96},[],{"trials":456,"activeCount":96},[],{"trials":458,"activeCount":96},[],{"intervention":460,"totalTrials":31,"cells":461},"cisplatin",{"EARLY_PHASE1":462,"PHASE1":464,"PHASE2":466,"PHASE3":479,"PHASE4":511,"NA":513},{"trials":463,"activeCount":96},[],{"trials":465,"activeCount":96},[],{"trials":467,"activeCount":96},[468],{"nctId":469,"briefTitle":470,"status":146,"phases":471,"primaryCompletion":472,"completion":472,"start":473,"enrollment":474,"conditions":475,"interventions":476},"NCT00702481","Study of Nimotuzumab and Cisplatin\u002FRadiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer",[86],"2019-09-03","2008-04-28",32,[20],[477,478],"Nimotuzumab","Cisplatin",{"trials":480,"activeCount":96},[481,490,498],{"nctId":482,"briefTitle":483,"status":115,"phases":484,"start":485,"enrollment":486,"conditions":487,"interventions":488},"NCT00003637","Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the Nasopharynx",[87],"1998-09",200,[20],[460,489],"fluorouracil",{"nctId":491,"briefTitle":492,"status":146,"phases":493,"completion":494,"start":495,"enrollment":486,"conditions":496,"interventions":497},"NCT00003576","Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery",[87],"2005-08","1997-01",[20],[460,489],{"nctId":499,"briefTitle":500,"status":115,"phases":501,"primaryCompletion":502,"completion":503,"start":504,"enrollment":505,"conditions":506,"interventions":507},"NCT00997906","Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC",[86,87],"2017-12-31","2023-12-31","2009-09-15",172,[20],[508,460,509,510],"carboplatin,","gemcitabine hydrochloride","paclitaxel",{"trials":512,"activeCount":96},[],{"trials":514,"activeCount":96},[],{"intervention":489,"totalTrials":516,"cells":517},3,{"EARLY_PHASE1":518,"PHASE1":520,"PHASE2":522,"PHASE3":536,"PHASE4":546,"NA":548},{"trials":519,"activeCount":96},[],{"trials":521,"activeCount":96},[],{"trials":523,"activeCount":96},[524],{"nctId":525,"briefTitle":526,"status":115,"phases":527,"start":528,"enrollment":529,"conditions":530,"interventions":532},"NCT00471484","Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery",[86],"2007-03",54,[531],"Liver Cancer",[533,534,489,535],"recombinant interferon alfa-2b","doxorubicin hydrochloride","oxaliplatin",{"trials":537,"activeCount":96},[538,542],{"nctId":482,"briefTitle":483,"status":115,"phases":539,"start":485,"enrollment":486,"conditions":540,"interventions":541},[87],[20],[460,489],{"nctId":491,"briefTitle":492,"status":146,"phases":543,"completion":494,"start":495,"enrollment":486,"conditions":544,"interventions":545},[87],[20],[460,489],{"trials":547,"activeCount":96},[],{"trials":549,"activeCount":96},[],{"intervention":510,"totalTrials":516,"cells":551},{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":579,"PHASE4":585,"NA":587},{"trials":553,"activeCount":96},[],{"trials":555,"activeCount":96},[],{"trials":557,"activeCount":96},[558,568],{"nctId":559,"briefTitle":560,"status":115,"phases":561,"primaryCompletion":562,"completion":563,"start":564,"enrollment":12,"conditions":565,"interventions":566},"NCT03429972","Regional Cryotherapy in Preventing Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients",[86],"2019-09","2020-06","2016-09",[15],[567],"Paclitaxel",{"nctId":569,"briefTitle":570,"status":104,"phases":571,"primaryCompletion":572,"start":573,"enrollment":574,"conditions":575,"interventions":576},"NCT00589238","Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery",[86],"2012-07","2008-01",16,[15],[577,578,534,510],"carboplatin","cyclophosphamide",{"trials":580,"activeCount":96},[581],{"nctId":499,"briefTitle":500,"status":115,"phases":582,"primaryCompletion":502,"completion":503,"start":504,"enrollment":505,"conditions":583,"interventions":584},[86,87],[20],[508,460,509,510],{"trials":586,"activeCount":96},[],{"trials":588,"activeCount":96},[],{"intervention":509,"totalTrials":590,"cells":591},2,{"EARLY_PHASE1":592,"PHASE1":594,"PHASE2":596,"PHASE3":609,"PHASE4":615,"NA":617},{"trials":593,"activeCount":96},[],{"trials":595,"activeCount":96},[],{"trials":597,"activeCount":96},[598],{"nctId":599,"briefTitle":600,"status":115,"phases":601,"primaryCompletion":602,"start":603,"enrollment":604,"conditions":605,"interventions":606},"NCT00690872","Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer",[86],"2014-12","2008-07",35,[20],[607,577,509,608],"autologous Epstein-Barr virus-specific cytotoxic T lymphocytes","polymerase chain reaction",{"trials":610,"activeCount":96},[611],{"nctId":499,"briefTitle":500,"status":115,"phases":612,"primaryCompletion":502,"completion":503,"start":504,"enrollment":505,"conditions":613,"interventions":614},[86,87],[20],[508,460,509,510],{"trials":616,"activeCount":96},[],{"trials":618,"activeCount":96},[],{"intervention":477,"totalTrials":590,"cells":620},{"EARLY_PHASE1":621,"PHASE1":623,"PHASE2":625,"PHASE3":631,"PHASE4":643,"NA":645},{"trials":622,"activeCount":96},[],{"trials":624,"activeCount":96},[],{"trials":626,"activeCount":96},[627],{"nctId":469,"briefTitle":470,"status":146,"phases":628,"primaryCompletion":472,"completion":472,"start":473,"enrollment":474,"conditions":629,"interventions":630},[86],[20],[477,478],{"trials":632,"activeCount":96},[633],{"nctId":634,"briefTitle":635,"status":115,"phases":636,"primaryCompletion":637,"completion":637,"start":638,"enrollment":639,"conditions":640,"interventions":642},"NCT00957086","Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer",[87],"2025-01-01","2009-08-13",710,[641],"Carcinoma, Squamous Cell of Head and Neck",[477],{"trials":644,"activeCount":96},[],{"trials":646,"activeCount":96},[],{"intervention":648,"totalTrials":166,"cells":649},"Acetylsalicylic acid",{"EARLY_PHASE1":650,"PHASE1":652,"PHASE2":654,"PHASE3":656,"PHASE4":667,"NA":669},{"trials":651,"activeCount":96},[],{"trials":653,"activeCount":96},[],{"trials":655,"activeCount":96},[],{"trials":657,"activeCount":96},[658],{"nctId":659,"briefTitle":660,"status":115,"phases":661,"primaryCompletion":662,"completion":662,"start":663,"enrollment":664,"conditions":665,"interventions":666},"NCT00565708","Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers",[87],"2024-06","2008-12",1587,[23],[648],{"trials":668,"activeCount":96},[],{"trials":670,"activeCount":96},[],{"intervention":508,"totalTrials":166,"cells":672},{"EARLY_PHASE1":673,"PHASE1":675,"PHASE2":677,"PHASE3":679,"PHASE4":685,"NA":687},{"trials":674,"activeCount":96},[],{"trials":676,"activeCount":96},[],{"trials":678,"activeCount":96},[],{"trials":680,"activeCount":96},[681],{"nctId":499,"briefTitle":500,"status":115,"phases":682,"primaryCompletion":502,"completion":503,"start":504,"enrollment":505,"conditions":683,"interventions":684},[86,87],[20],[508,460,509,510],{"trials":686,"activeCount":96},[],{"trials":688,"activeCount":96},[],{"intervention":578,"totalTrials":516,"cells":690},{"EARLY_PHASE1":691,"PHASE1":693,"PHASE2":695,"PHASE3":724,"PHASE4":726,"NA":728},{"trials":692,"activeCount":96},[],{"trials":694,"activeCount":96},[],{"trials":696,"activeCount":96},[697,701,710],{"nctId":569,"briefTitle":570,"status":104,"phases":698,"primaryCompletion":572,"start":573,"enrollment":574,"conditions":699,"interventions":700},[86],[15],[577,578,534,510],{"nctId":702,"briefTitle":703,"status":115,"phases":704,"start":705,"enrollment":706,"conditions":707,"interventions":708},"NCT00801411","Cyclophosphamide and Docetaxel or Doxorubicin in Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed by Surgery",[86],"2008-10",318,[15],[578,709,534],"docetaxel",{"nctId":711,"briefTitle":712,"status":115,"phases":713,"primaryCompletion":714,"start":715,"enrollment":716,"conditions":717,"interventions":718},"NCT00687648","Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer",[86],"2010-04","2008-05",70,[15],[719,578,720,721,722,723],"anastrozole","exemestane","letrozole","methotrexate","prednisolone",{"trials":725,"activeCount":96},[],{"trials":727,"activeCount":96},[],{"trials":729,"activeCount":96},[],{"intervention":534,"totalTrials":516,"cells":731},{"EARLY_PHASE1":732,"PHASE1":734,"PHASE2":736,"PHASE3":750,"PHASE4":752,"NA":754},{"trials":733,"activeCount":96},[],{"trials":735,"activeCount":96},[],{"trials":737,"activeCount":96},[738,742,746],{"nctId":569,"briefTitle":570,"status":104,"phases":739,"primaryCompletion":572,"start":573,"enrollment":574,"conditions":740,"interventions":741},[86],[15],[577,578,534,510],{"nctId":702,"briefTitle":703,"status":115,"phases":743,"start":705,"enrollment":706,"conditions":744,"interventions":745},[86],[15],[578,709,534],{"nctId":525,"briefTitle":526,"status":115,"phases":747,"start":528,"enrollment":529,"conditions":748,"interventions":749},[86],[531],[533,534,489,535],{"trials":751,"activeCount":96},[],{"trials":753,"activeCount":96},[],{"trials":755,"activeCount":96},[],{"intervention":757,"totalTrials":590,"cells":758},"Oxaliplatin",{"EARLY_PHASE1":759,"PHASE1":761,"PHASE2":774,"PHASE3":780,"PHASE4":782,"NA":784},{"trials":760,"activeCount":96},[],{"trials":762,"activeCount":96},[763],{"nctId":764,"briefTitle":765,"status":104,"phases":766,"primaryCompletion":767,"completion":767,"start":768,"enrollment":516,"conditions":769,"interventions":771},"NCT02720926","Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer",[85],"2012-01","2011-09",[23,770],"Gastric Cancer",[772,757,773],"Xeloda,","TKI258",{"trials":775,"activeCount":96},[776],{"nctId":525,"briefTitle":526,"status":115,"phases":777,"start":528,"enrollment":529,"conditions":778,"interventions":779},[86],[531],[533,534,489,535],{"trials":781,"activeCount":96},[],{"trials":783,"activeCount":96},[],{"trials":785,"activeCount":96},[],{"intervention":577,"totalTrials":590,"cells":787},{"EARLY_PHASE1":788,"PHASE1":790,"PHASE2":792,"PHASE3":802,"PHASE4":804,"NA":806},{"trials":789,"activeCount":96},[],{"trials":791,"activeCount":96},[],{"trials":793,"activeCount":96},[794,798],{"nctId":599,"briefTitle":600,"status":115,"phases":795,"primaryCompletion":602,"start":603,"enrollment":604,"conditions":796,"interventions":797},[86],[20],[607,577,509,608],{"nctId":569,"briefTitle":570,"status":104,"phases":799,"primaryCompletion":572,"start":573,"enrollment":574,"conditions":800,"interventions":801},[86],[15],[577,578,534,510],{"trials":803,"activeCount":96},[],{"trials":805,"activeCount":96},[],{"trials":807,"activeCount":96},[],{"intervention":809,"totalTrials":590,"cells":810},"Capecitabine",{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":826,"PHASE3":838,"PHASE4":840,"NA":842},{"trials":812,"activeCount":96},[],{"trials":814,"activeCount":96},[815],{"nctId":816,"briefTitle":817,"status":146,"phases":818,"primaryCompletion":819,"completion":819,"start":820,"enrollment":821,"conditions":822,"interventions":824},"NCT04664829","The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC",[85],"2025-08-04","2020-10-01",12,[823],"Metastatic Triple-Negative Breast Carcinoma",[825,809],"Bexarotene",{"trials":827,"activeCount":96},[828],{"nctId":829,"briefTitle":830,"status":104,"phases":831,"primaryCompletion":832,"completion":832,"start":833,"enrollment":516,"conditions":834,"interventions":836},"NCT07166367","Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer",[86],"2020-01-14","2016-08-11",[835],"HER2-positive Breast Cancer",[837,809],"ASLAN001",{"trials":839,"activeCount":96},[],{"trials":841,"activeCount":96},[],{"trials":843,"activeCount":96},[],{"intervention":111,"totalTrials":590,"cells":845},{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":850,"PHASE3":860,"PHASE4":862,"NA":864},{"trials":847,"activeCount":96},[],{"trials":849,"activeCount":96},[],{"trials":851,"activeCount":96},[852,856],{"nctId":102,"briefTitle":103,"status":104,"phases":853,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":854,"interventions":855},[86],[28],[111,92],{"nctId":135,"briefTitle":136,"status":115,"phases":857,"primaryCompletion":138,"completion":138,"start":139,"enrollment":140,"conditions":858,"interventions":859},[86],[25],[111,92],{"trials":861,"activeCount":96},[],{"trials":863,"activeCount":96},[],{"trials":865,"activeCount":96},[],{"intervention":867,"totalTrials":590,"cells":868},"Pembrolizumab",{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":882,"PHASE3":896,"PHASE4":898,"NA":900},{"trials":870,"activeCount":96},[],{"trials":872,"activeCount":96},[873],{"nctId":874,"briefTitle":875,"status":115,"phases":876,"primaryCompletion":877,"completion":877,"start":878,"enrollment":879,"conditions":880,"interventions":881},"NCT04224480","Longitudinal Immune-phenotyping of HCC Following MK-3475",[85],"2025-12-31","2019-12-10",8,[18],[867],{"trials":883,"activeCount":96},[884],{"nctId":885,"briefTitle":886,"status":146,"phases":887,"primaryCompletion":888,"completion":888,"start":889,"enrollment":8,"conditions":890,"interventions":891},"NCT03984578","Window of Opportunity Study in Colorectal Cancer",[86],"2025-02-28","2019-06-12",[23],[892,867,893,867,894,895],"CAPEOX","Capecitabine\u002F 5-FU","CAPEOX\u002FPembrolizumab","Pembrolizumab alone",{"trials":897,"activeCount":96},[],{"trials":899,"activeCount":96},[],{"trials":901,"activeCount":96},[],{"intervention":122,"totalTrials":590,"cells":903},{"EARLY_PHASE1":904,"PHASE1":906,"PHASE2":908,"PHASE3":918,"PHASE4":920,"NA":922},{"trials":905,"activeCount":96},[],{"trials":907,"activeCount":96},[],{"trials":909,"activeCount":96},[910,914],{"nctId":113,"briefTitle":114,"status":115,"phases":911,"primaryCompletion":117,"completion":117,"start":118,"enrollment":108,"conditions":912,"interventions":913},[85,86],[120],[122,92,123],{"nctId":125,"briefTitle":126,"status":104,"phases":915,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":916,"interventions":917},[85,86],[120],[92,122],{"trials":919,"activeCount":96},[],{"trials":921,"activeCount":96},[],{"trials":923,"activeCount":96},[],{"intervention":607,"totalTrials":166,"cells":925},{"EARLY_PHASE1":926,"PHASE1":928,"PHASE2":930,"PHASE3":936,"PHASE4":938,"NA":940},{"trials":927,"activeCount":96},[],{"trials":929,"activeCount":96},[],{"trials":931,"activeCount":96},[932],{"nctId":599,"briefTitle":600,"status":115,"phases":933,"primaryCompletion":602,"start":603,"enrollment":604,"conditions":934,"interventions":935},[86],[20],[607,577,509,608],{"trials":937,"activeCount":96},[],{"trials":939,"activeCount":96},[],{"trials":941,"activeCount":96},[],{"intervention":608,"totalTrials":166,"cells":943},{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":948,"PHASE3":954,"PHASE4":956,"NA":958},{"trials":945,"activeCount":96},[],{"trials":947,"activeCount":96},[],{"trials":949,"activeCount":96},[950],{"nctId":599,"briefTitle":600,"status":115,"phases":951,"primaryCompletion":602,"start":603,"enrollment":604,"conditions":952,"interventions":953},[86],[20],[607,577,509,608],{"trials":955,"activeCount":96},[],{"trials":957,"activeCount":96},[],{"trials":959,"activeCount":96},[],{"intervention":961,"totalTrials":166,"cells":962},"Ibrutinib",{"EARLY_PHASE1":963,"PHASE1":965,"PHASE2":967,"PHASE3":978,"PHASE4":980,"NA":982},{"trials":964,"activeCount":96},[],{"trials":966,"activeCount":96},[],{"trials":968,"activeCount":96},[969],{"nctId":970,"briefTitle":971,"status":104,"phases":972,"primaryCompletion":973,"completion":973,"start":974,"enrollment":26,"conditions":975,"interventions":977},"NCT03093831","Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma",[86],"2020-07-17","2016-07-08",[976],"Lymphoma, B-Cell, Marginal Zone",[961],{"trials":979,"activeCount":96},[],{"trials":981,"activeCount":96},[],{"trials":983,"activeCount":96},[],{"intervention":985,"totalTrials":166,"cells":986},"oral cyclophosphamide",{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":991,"PHASE3":1002,"PHASE4":1004,"NA":1006},{"trials":988,"activeCount":96},[],{"trials":990,"activeCount":96},[],{"trials":992,"activeCount":96},[993],{"nctId":994,"briefTitle":995,"status":146,"phases":996,"primaryCompletion":997,"completion":997,"start":998,"enrollment":342,"conditions":999,"interventions":1001},"NCT01716689","Clinical Study of Metronomic Oral Cyclophosphamide in Patients With Advanced Sarcomas",[86],"2016-10","2012-06",[1000],"Sarcoma",[985],{"trials":1003,"activeCount":96},[],{"trials":1005,"activeCount":96},[],{"trials":1007,"activeCount":96},[],{"intervention":1009,"totalTrials":166,"cells":1010},"Neoadjuvant Docetaxel and Cyclophosphamide",{"EARLY_PHASE1":1011,"PHASE1":1013,"PHASE2":1015,"PHASE3":1026,"PHASE4":1028,"NA":1030},{"trials":1012,"activeCount":96},[],{"trials":1014,"activeCount":96},[],{"trials":1016,"activeCount":96},[1017],{"nctId":1018,"briefTitle":1019,"status":146,"phases":1020,"primaryCompletion":1021,"completion":1021,"start":1022,"enrollment":1023,"conditions":1024,"interventions":1025},"NCT01540110","Study of Neoadjuvant Docetaxel and Cyclophosphamide in Locally Advanced or Node Positive Primary Breast Cancer With Companion Pharmacokinetic and Pharmacogenomic Analyses",[86],"2015-10-20","2010-08-11",21,[15],[1009],{"trials":1027,"activeCount":96},[],{"trials":1029,"activeCount":96},[],{"trials":1031,"activeCount":96},[],{"intervention":892,"totalTrials":166,"cells":1033},{"EARLY_PHASE1":1034,"PHASE1":1036,"PHASE2":1038,"PHASE3":1044,"PHASE4":1046,"NA":1048},{"trials":1035,"activeCount":96},[],{"trials":1037,"activeCount":96},[],{"trials":1039,"activeCount":96},[1040],{"nctId":885,"briefTitle":886,"status":146,"phases":1041,"primaryCompletion":888,"completion":888,"start":889,"enrollment":8,"conditions":1042,"interventions":1043},[86],[23],[892,867,893,867,894,895],{"trials":1045,"activeCount":96},[],{"trials":1047,"activeCount":96},[],{"trials":1049,"activeCount":96},[],{"intervention":893,"totalTrials":166,"cells":1051},{"EARLY_PHASE1":1052,"PHASE1":1054,"PHASE2":1056,"PHASE3":1062,"PHASE4":1064,"NA":1066},{"trials":1053,"activeCount":96},[],{"trials":1055,"activeCount":96},[],{"trials":1057,"activeCount":96},[1058],{"nctId":885,"briefTitle":886,"status":146,"phases":1059,"primaryCompletion":888,"completion":888,"start":889,"enrollment":8,"conditions":1060,"interventions":1061},[86],[23],[892,867,893,867,894,895],{"trials":1063,"activeCount":96},[],{"trials":1065,"activeCount":96},[],{"trials":1067,"activeCount":96},[],{"intervention":894,"totalTrials":166,"cells":1069},{"EARLY_PHASE1":1070,"PHASE1":1072,"PHASE2":1074,"PHASE3":1080,"PHASE4":1082,"NA":1084},{"trials":1071,"activeCount":96},[],{"trials":1073,"activeCount":96},[],{"trials":1075,"activeCount":96},[1076],{"nctId":885,"briefTitle":886,"status":146,"phases":1077,"primaryCompletion":888,"completion":888,"start":889,"enrollment":8,"conditions":1078,"interventions":1079},[86],[23],[892,867,893,867,894,895],{"trials":1081,"activeCount":96},[],{"trials":1083,"activeCount":96},[],{"trials":1085,"activeCount":96},[],{"intervention":895,"totalTrials":166,"cells":1087},{"EARLY_PHASE1":1088,"PHASE1":1090,"PHASE2":1092,"PHASE3":1098,"PHASE4":1100,"NA":1102},{"trials":1089,"activeCount":96},[],{"trials":1091,"activeCount":96},[],{"trials":1093,"activeCount":96},[1094],{"nctId":885,"briefTitle":886,"status":146,"phases":1095,"primaryCompletion":888,"completion":888,"start":889,"enrollment":8,"conditions":1096,"interventions":1097},[86],[23],[892,867,893,867,894,895],{"trials":1099,"activeCount":96},[],{"trials":1101,"activeCount":96},[],{"trials":1103,"activeCount":96},[],{"intervention":1105,"totalTrials":166,"cells":1106},"Gefitinib",{"EARLY_PHASE1":1107,"PHASE1":1109,"PHASE2":1111,"PHASE3":1122,"PHASE4":1124,"NA":1126},{"trials":1108,"activeCount":96},[],{"trials":1110,"activeCount":96},[],{"trials":1112,"activeCount":96},[1113],{"nctId":1114,"briefTitle":1115,"status":146,"phases":1116,"primaryCompletion":1117,"completion":1117,"start":1118,"enrollment":1119,"conditions":1120,"interventions":1121},"NCT02804776","PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery",[86],"2018-02-21","2015-01-27",15,[30],[1105],{"trials":1123,"activeCount":96},[],{"trials":1125,"activeCount":96},[],{"trials":1127,"activeCount":96},[],{"intervention":1129,"totalTrials":166,"cells":1130},"AZD6244 and sorafenib",{"EARLY_PHASE1":1131,"PHASE1":1133,"PHASE2":1135,"PHASE3":1146,"PHASE4":1148,"NA":1150},{"trials":1132,"activeCount":96},[],{"trials":1134,"activeCount":96},[],{"trials":1136,"activeCount":96},[1137],{"nctId":1138,"briefTitle":1139,"status":104,"phases":1140,"primaryCompletion":1141,"completion":1142,"start":1143,"enrollment":260,"conditions":1144,"interventions":1145},"NCT01029418","AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma",[85,86],"2014-02","2015-01","2009-11",[18],[1129],{"trials":1147,"activeCount":96},[],{"trials":1149,"activeCount":96},[],{"trials":1151,"activeCount":96},[],{"intervention":123,"totalTrials":166,"cells":1153},{"EARLY_PHASE1":1154,"PHASE1":1156,"PHASE2":1158,"PHASE3":1164,"PHASE4":1166,"NA":1168},{"trials":1155,"activeCount":96},[],{"trials":1157,"activeCount":96},[],{"trials":1159,"activeCount":96},[1160],{"nctId":113,"briefTitle":114,"status":115,"phases":1161,"primaryCompletion":117,"completion":117,"start":118,"enrollment":108,"conditions":1162,"interventions":1163},[85,86],[120],[122,92,123],{"trials":1165,"activeCount":96},[],{"trials":1167,"activeCount":96},[],{"trials":1169,"activeCount":96},[],{"intervention":709,"totalTrials":166,"cells":1171},{"EARLY_PHASE1":1172,"PHASE1":1174,"PHASE2":1176,"PHASE3":1182,"PHASE4":1184,"NA":1186},{"trials":1173,"activeCount":96},[],{"trials":1175,"activeCount":96},[],{"trials":1177,"activeCount":96},[1178],{"nctId":702,"briefTitle":703,"status":115,"phases":1179,"start":705,"enrollment":706,"conditions":1180,"interventions":1181},[86],[15],[578,709,534],{"trials":1183,"activeCount":96},[],{"trials":1185,"activeCount":96},[],{"trials":1187,"activeCount":96},[],{"intervention":1189,"totalTrials":166,"cells":1190},"Regorafenib",{"EARLY_PHASE1":1191,"PHASE1":1193,"PHASE2":1195,"PHASE3":1205,"PHASE4":1207,"NA":1209},{"trials":1192,"activeCount":96},[],{"trials":1194,"activeCount":96},[],{"trials":1196,"activeCount":96},[1197],{"nctId":1198,"briefTitle":1199,"status":146,"phases":1200,"primaryCompletion":106,"completion":106,"start":1201,"enrollment":1023,"conditions":1202,"interventions":1204},"NCT02736305","Use of Regorafenib in Recurrent Epithelial Ovarian Cancer",[86],"2016-02-03",[1203],"Ovarian Neoplasms",[1189],{"trials":1206,"activeCount":96},[],{"trials":1208,"activeCount":96},[],{"trials":1210,"activeCount":96},[],{"intervention":719,"totalTrials":166,"cells":1212},{"EARLY_PHASE1":1213,"PHASE1":1215,"PHASE2":1217,"PHASE3":1223,"PHASE4":1225,"NA":1227},{"trials":1214,"activeCount":96},[],{"trials":1216,"activeCount":96},[],{"trials":1218,"activeCount":96},[1219],{"nctId":711,"briefTitle":712,"status":115,"phases":1220,"primaryCompletion":714,"start":715,"enrollment":716,"conditions":1221,"interventions":1222},[86],[15],[719,578,720,721,722,723],{"trials":1224,"activeCount":96},[],{"trials":1226,"activeCount":96},[],{"trials":1228,"activeCount":96},[],{"intervention":720,"totalTrials":166,"cells":1230},{"EARLY_PHASE1":1231,"PHASE1":1233,"PHASE2":1235,"PHASE3":1241,"PHASE4":1243,"NA":1245},{"trials":1232,"activeCount":96},[],{"trials":1234,"activeCount":96},[],{"trials":1236,"activeCount":96},[1237],{"nctId":711,"briefTitle":712,"status":115,"phases":1238,"primaryCompletion":714,"start":715,"enrollment":716,"conditions":1239,"interventions":1240},[86],[15],[719,578,720,721,722,723],{"trials":1242,"activeCount":96},[],{"trials":1244,"activeCount":96},[],{"trials":1246,"activeCount":96},[],{"intervention":721,"totalTrials":166,"cells":1248},{"EARLY_PHASE1":1249,"PHASE1":1251,"PHASE2":1253,"PHASE3":1259,"PHASE4":1261,"NA":1263},{"trials":1250,"activeCount":96},[],{"trials":1252,"activeCount":96},[],{"trials":1254,"activeCount":96},[1255],{"nctId":711,"briefTitle":712,"status":115,"phases":1256,"primaryCompletion":714,"start":715,"enrollment":716,"conditions":1257,"interventions":1258},[86],[15],[719,578,720,721,722,723],{"trials":1260,"activeCount":96},[],{"trials":1262,"activeCount":96},[],{"trials":1264,"activeCount":96},[],{"intervention":722,"totalTrials":166,"cells":1266},{"EARLY_PHASE1":1267,"PHASE1":1269,"PHASE2":1271,"PHASE3":1277,"PHASE4":1279,"NA":1281},{"trials":1268,"activeCount":96},[],{"trials":1270,"activeCount":96},[],{"trials":1272,"activeCount":96},[1273],{"nctId":711,"briefTitle":712,"status":115,"phases":1274,"primaryCompletion":714,"start":715,"enrollment":716,"conditions":1275,"interventions":1276},[86],[15],[719,578,720,721,722,723],{"trials":1278,"activeCount":96},[],{"trials":1280,"activeCount":96},[],{"trials":1282,"activeCount":96},[],{"intervention":723,"totalTrials":166,"cells":1284},{"EARLY_PHASE1":1285,"PHASE1":1287,"PHASE2":1289,"PHASE3":1295,"PHASE4":1297,"NA":1299},{"trials":1286,"activeCount":96},[],{"trials":1288,"activeCount":96},[],{"trials":1290,"activeCount":96},[1291],{"nctId":711,"briefTitle":712,"status":115,"phases":1292,"primaryCompletion":714,"start":715,"enrollment":716,"conditions":1293,"interventions":1294},[86],[15],[719,578,720,721,722,723],{"trials":1296,"activeCount":96},[],{"trials":1298,"activeCount":96},[],{"trials":1300,"activeCount":96},[],{"intervention":533,"totalTrials":166,"cells":1302},{"EARLY_PHASE1":1303,"PHASE1":1305,"PHASE2":1307,"PHASE3":1313,"PHASE4":1315,"NA":1317},{"trials":1304,"activeCount":96},[],{"trials":1306,"activeCount":96},[],{"trials":1308,"activeCount":96},[1309],{"nctId":525,"briefTitle":526,"status":115,"phases":1310,"start":528,"enrollment":529,"conditions":1311,"interventions":1312},[86],[531],[533,534,489,535],{"trials":1314,"activeCount":96},[],{"trials":1316,"activeCount":96},[],{"trials":1318,"activeCount":96},[],{"intervention":1320,"totalTrials":166,"cells":1321},"O-ICE",{"EARLY_PHASE1":1322,"PHASE1":1324,"PHASE2":1326,"PHASE3":1339,"PHASE4":1341,"NA":1343},{"trials":1323,"activeCount":96},[],{"trials":1325,"activeCount":96},[],{"trials":1327,"activeCount":96},[1328],{"nctId":1329,"briefTitle":1330,"status":146,"phases":1331,"primaryCompletion":1332,"completion":1333,"start":1334,"enrollment":1335,"conditions":1336,"interventions":1338},"NCT02412267","Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)",[86],"2015-12","2016-03","2011-04",17,[1337],"Diffuse Large B-cell Lymphoma",[1320],{"trials":1340,"activeCount":96},[],{"trials":1342,"activeCount":96},[],{"trials":1344,"activeCount":96},[],{"intervention":1346,"totalTrials":166,"cells":1347},"Ad5F35-LMP1\u002FLMP2-transduced autologous dendritic cells",{"EARLY_PHASE1":1348,"PHASE1":1350,"PHASE2":1352,"PHASE3":1363,"PHASE4":1365,"NA":1367},{"trials":1349,"activeCount":96},[],{"trials":1351,"activeCount":96},[],{"trials":1353,"activeCount":96},[1354],{"nctId":1355,"briefTitle":1356,"status":115,"phases":1357,"primaryCompletion":1358,"start":1359,"enrollment":604,"conditions":1360,"interventions":1361},"NCT00589186","Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer",[86],"2009-12","2007-11",[20],[1346,1362],"celecoxib",{"trials":1364,"activeCount":96},[],{"trials":1366,"activeCount":96},[],{"trials":1368,"activeCount":96},[],{"intervention":1362,"totalTrials":166,"cells":1370},{"EARLY_PHASE1":1371,"PHASE1":1373,"PHASE2":1375,"PHASE3":1381,"PHASE4":1383,"NA":1385},{"trials":1372,"activeCount":96},[],{"trials":1374,"activeCount":96},[],{"trials":1376,"activeCount":96},[1377],{"nctId":1355,"briefTitle":1356,"status":115,"phases":1378,"primaryCompletion":1358,"start":1359,"enrollment":604,"conditions":1379,"interventions":1380},[86],[20],[1346,1362],{"trials":1382,"activeCount":96},[],{"trials":1384,"activeCount":96},[],{"trials":1386,"activeCount":96},[],{"intervention":1388,"totalTrials":166,"cells":1389},"GIFOX-Bortezomib",{"EARLY_PHASE1":1390,"PHASE1":1392,"PHASE2":1394,"PHASE3":1406,"PHASE4":1408,"NA":1410},{"trials":1391,"activeCount":96},[],{"trials":1393,"activeCount":96},[],{"trials":1395,"activeCount":96},[1396],{"nctId":1397,"briefTitle":1398,"status":104,"phases":1399,"primaryCompletion":1400,"completion":1401,"start":1402,"enrollment":9,"conditions":1403,"interventions":1405},"NCT02808091","Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK\u002FT Cell Lymphoma",[86],"2013-11","2014-03","2011-03",[1404],"Extranodal NK-T-CELL LYMPHOMA",[1388,1388],{"trials":1407,"activeCount":96},[],{"trials":1409,"activeCount":96},[],{"trials":1411,"activeCount":96},[],{"intervention":1413,"totalTrials":166,"cells":1414},"Trastuzumab, TS ONE, Cisplatin",{"EARLY_PHASE1":1415,"PHASE1":1417,"PHASE2":1419,"PHASE3":1431,"PHASE4":1433,"NA":1435},{"trials":1416,"activeCount":96},[],{"trials":1418,"activeCount":96},[],{"trials":1420,"activeCount":96},[1421],{"nctId":1422,"briefTitle":1423,"status":146,"phases":1424,"primaryCompletion":1425,"completion":1426,"start":1427,"enrollment":260,"conditions":1428,"interventions":1430},"NCT01736410","A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer",[86],"2013-04","2013-05","2010-05",[1429],"HER 2 Positive Advanced Gastric Cancer",[1413],{"trials":1432,"activeCount":96},[],{"trials":1434,"activeCount":96},[],{"trials":1436,"activeCount":96},[],{"intervention":837,"totalTrials":166,"cells":1438},{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1443,"PHASE3":1449,"PHASE4":1451,"NA":1453},{"trials":1440,"activeCount":96},[],{"trials":1442,"activeCount":96},[],{"trials":1444,"activeCount":96},[1445],{"nctId":829,"briefTitle":830,"status":104,"phases":1446,"primaryCompletion":832,"completion":832,"start":833,"enrollment":516,"conditions":1447,"interventions":1448},[86],[835],[837,809],{"trials":1450,"activeCount":96},[],{"trials":1452,"activeCount":96},[],{"trials":1454,"activeCount":96},[],{"intervention":1456,"totalTrials":166,"cells":1457},"PRL3-zumab",{"EARLY_PHASE1":1458,"PHASE1":1460,"PHASE2":1462,"PHASE3":1471,"PHASE4":1473,"NA":1475},{"trials":1459,"activeCount":96},[],{"trials":1461,"activeCount":96},[],{"trials":1463,"activeCount":96},[1464],{"nctId":1465,"briefTitle":1466,"status":146,"phases":1467,"primaryCompletion":1468,"completion":1468,"start":472,"enrollment":11,"conditions":1469,"interventions":1470},"NCT04118114","Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors",[86],"2025-10-17",[770,18,448],[1456],{"trials":1472,"activeCount":96},[],{"trials":1474,"activeCount":96},[],{"trials":1476,"activeCount":96},[],{"intervention":1478,"totalTrials":166,"cells":1479},"Selinexor",{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1495,"PHASE3":1497,"PHASE4":1499,"NA":1501},{"trials":1481,"activeCount":96},[],{"trials":1483,"activeCount":96},[1484],{"nctId":1485,"briefTitle":1486,"status":146,"phases":1487,"primaryCompletion":1488,"completion":1488,"start":1489,"enrollment":1490,"conditions":1491,"interventions":1493},"NCT03212937","Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma",[85],"2020-11","2016-07-01",11,[1492],"Peripheral T-cell Lymphoma",[1478,1494],"ICE Chemotherapy",{"trials":1496,"activeCount":96},[],{"trials":1498,"activeCount":96},[],{"trials":1500,"activeCount":96},[],{"trials":1502,"activeCount":96},[],{"intervention":1494,"totalTrials":166,"cells":1504},{"EARLY_PHASE1":1505,"PHASE1":1507,"PHASE2":1513,"PHASE3":1515,"PHASE4":1517,"NA":1519},{"trials":1506,"activeCount":96},[],{"trials":1508,"activeCount":96},[1509],{"nctId":1485,"briefTitle":1486,"status":146,"phases":1510,"primaryCompletion":1488,"completion":1488,"start":1489,"enrollment":1490,"conditions":1511,"interventions":1512},[85],[1492],[1478,1494],{"trials":1514,"activeCount":96},[],{"trials":1516,"activeCount":96},[],{"trials":1518,"activeCount":96},[],{"trials":1520,"activeCount":96},[],{"intervention":772,"totalTrials":166,"cells":1522},{"EARLY_PHASE1":1523,"PHASE1":1525,"PHASE2":1531,"PHASE3":1533,"PHASE4":1535,"NA":1537},{"trials":1524,"activeCount":96},[],{"trials":1526,"activeCount":96},[1527],{"nctId":764,"briefTitle":765,"status":104,"phases":1528,"primaryCompletion":767,"completion":767,"start":768,"enrollment":516,"conditions":1529,"interventions":1530},[85],[23,770],[772,757,773],{"trials":1532,"activeCount":96},[],{"trials":1534,"activeCount":96},[],{"trials":1536,"activeCount":96},[],{"trials":1538,"activeCount":96},[],{"intervention":773,"totalTrials":166,"cells":1540},{"EARLY_PHASE1":1541,"PHASE1":1543,"PHASE2":1549,"PHASE3":1551,"PHASE4":1553,"NA":1555},{"trials":1542,"activeCount":96},[],{"trials":1544,"activeCount":96},[1545],{"nctId":764,"briefTitle":765,"status":104,"phases":1546,"primaryCompletion":767,"completion":767,"start":768,"enrollment":516,"conditions":1547,"interventions":1548},[85],[23,770],[772,757,773],{"trials":1550,"activeCount":96},[],{"trials":1552,"activeCount":96},[],{"trials":1554,"activeCount":96},[],{"trials":1556,"activeCount":96},[],{"intervention":1558,"totalTrials":166,"cells":1559},"Tamoxifen",{"EARLY_PHASE1":1560,"PHASE1":1562,"PHASE2":1573,"PHASE3":1575,"PHASE4":1577,"NA":1579},{"trials":1561,"activeCount":96},[],{"trials":1563,"activeCount":96},[1564],{"nctId":1565,"briefTitle":1566,"status":115,"phases":1567,"primaryCompletion":1568,"completion":1568,"start":1569,"enrollment":1570,"conditions":1571,"interventions":1572},"NCT04961632","Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376",[85],"2025-11","2020-12-23",75,[15],[1558,1558],{"trials":1574,"activeCount":96},[],{"trials":1576,"activeCount":96},[],{"trials":1578,"activeCount":96},[],{"trials":1580,"activeCount":96},[],{"intervention":825,"totalTrials":166,"cells":1582},{"EARLY_PHASE1":1583,"PHASE1":1585,"PHASE2":1591,"PHASE3":1593,"PHASE4":1595,"NA":1597},{"trials":1584,"activeCount":96},[],{"trials":1586,"activeCount":96},[1587],{"nctId":816,"briefTitle":817,"status":146,"phases":1588,"primaryCompletion":819,"completion":819,"start":820,"enrollment":821,"conditions":1589,"interventions":1590},[85],[823],[825,809],{"trials":1592,"activeCount":96},[],{"trials":1594,"activeCount":96},[],{"trials":1596,"activeCount":96},[],{"trials":1598,"activeCount":96},[],{"intervention":1600,"totalTrials":166,"cells":1601},"ASLAN001+ CAPOX",{"EARLY_PHASE1":1602,"PHASE1":1604,"PHASE2":1616,"PHASE3":1618,"PHASE4":1620,"NA":1622},{"trials":1603,"activeCount":96},[],{"trials":1605,"activeCount":96},[1606],{"nctId":1607,"briefTitle":1608,"status":115,"phases":1609,"primaryCompletion":1610,"completion":1610,"start":1611,"enrollment":160,"conditions":1612,"interventions":1614},"NCT02435927","ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin",[85],"2021-06","2014-08",[1613],"Solid Tumors",[1600,1615],"ASLAN001 + mFolfox6",{"trials":1617,"activeCount":96},[],{"trials":1619,"activeCount":96},[],{"trials":1621,"activeCount":96},[],{"trials":1623,"activeCount":96},[],{"intervention":1615,"totalTrials":166,"cells":1625},{"EARLY_PHASE1":1626,"PHASE1":1628,"PHASE2":1634,"PHASE3":1636,"PHASE4":1638,"NA":1640},{"trials":1627,"activeCount":96},[],{"trials":1629,"activeCount":96},[1630],{"nctId":1607,"briefTitle":1608,"status":115,"phases":1631,"primaryCompletion":1610,"completion":1610,"start":1611,"enrollment":160,"conditions":1632,"interventions":1633},[85],[1613],[1600,1615],{"trials":1635,"activeCount":96},[],{"trials":1637,"activeCount":96},[],{"trials":1639,"activeCount":96},[],{"trials":1641,"activeCount":96},[],{"intervention":1643,"totalTrials":166,"cells":1644},"Vinorelbine",{"EARLY_PHASE1":1645,"PHASE1":1647,"PHASE2":1659,"PHASE3":1661,"PHASE4":1663,"NA":1665},{"trials":1646,"activeCount":96},[],{"trials":1648,"activeCount":96},[1649],{"nctId":1650,"briefTitle":1651,"status":146,"phases":1652,"primaryCompletion":1653,"completion":1654,"start":1655,"enrollment":260,"conditions":1656,"interventions":1657},"NCT00702182","Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung Cancer",[85],"2012-04","2012-10","2008-04",[28],[1643,1643,1658],"Erlotinib",{"trials":1660,"activeCount":96},[],{"trials":1662,"activeCount":96},[],{"trials":1664,"activeCount":96},[],{"trials":1666,"activeCount":96},[],{"intervention":1658,"totalTrials":166,"cells":1668},{"EARLY_PHASE1":1669,"PHASE1":1671,"PHASE2":1677,"PHASE3":1679,"PHASE4":1681,"NA":1683},{"trials":1670,"activeCount":96},[],{"trials":1672,"activeCount":96},[1673],{"nctId":1650,"briefTitle":1651,"status":146,"phases":1674,"primaryCompletion":1653,"completion":1654,"start":1655,"enrollment":260,"conditions":1675,"interventions":1676},[85],[28],[1643,1643,1658],{"trials":1678,"activeCount":96},[],{"trials":1680,"activeCount":96},[],{"trials":1682,"activeCount":96},[],{"trials":1684,"activeCount":96},[],{"intervention":1686,"totalTrials":166,"cells":1687},"PIPAC",{"EARLY_PHASE1":1688,"PHASE1":1690,"PHASE2":1703,"PHASE3":1705,"PHASE4":1707,"NA":1709},{"trials":1689,"activeCount":96},[],{"trials":1691,"activeCount":96},[1692],{"nctId":1693,"briefTitle":1694,"status":1695,"phases":1696,"primaryCompletion":1697,"completion":1697,"start":1698,"enrollment":1699,"conditions":1700,"interventions":1702},"NCT04956068","PIPAC for Peritoneal Metastases","SUSPENDED",[85],"2026-11","2021-05-20",25,[1701],"Peritoneal Metastases",[1686],{"trials":1704,"activeCount":96},[],{"trials":1706,"activeCount":96},[],{"trials":1708,"activeCount":96},[],{"trials":1710,"activeCount":96},[],{"intervention":1712,"totalTrials":166,"cells":1713},"Gefitinib and BKM120",{"EARLY_PHASE1":1714,"PHASE1":1716,"PHASE2":1728,"PHASE3":1730,"PHASE4":1732,"NA":1734},{"trials":1715,"activeCount":96},[],{"trials":1717,"activeCount":96},[1718],{"nctId":1719,"briefTitle":1720,"status":146,"phases":1721,"primaryCompletion":1722,"completion":1723,"start":1724,"enrollment":1725,"conditions":1726,"interventions":1727},"NCT01570296","A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR",[85],"2016-02-22","2018-12-17","2011-10-03",38,[28,1613],[1712],{"trials":1729,"activeCount":96},[],{"trials":1731,"activeCount":96},[],{"trials":1733,"activeCount":96},[],{"trials":1735,"activeCount":96},[],{"intervention":1737,"totalTrials":166,"cells":1738},"oxaliplatin, irinotecan, capecitabine",{"EARLY_PHASE1":1739,"PHASE1":1741,"PHASE2":1752,"PHASE3":1754,"PHASE4":1756,"NA":1758},{"trials":1740,"activeCount":96},[],{"trials":1742,"activeCount":96},[1743],{"nctId":1744,"briefTitle":1745,"status":146,"phases":1746,"primaryCompletion":1747,"completion":1747,"start":1748,"enrollment":8,"conditions":1749,"interventions":1751},"NCT02368860","OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic Adenocarcinoma",[85],"2020-05-21","2013-09-17",[1750],"Pancreatic Cancer",[1737],{"trials":1753,"activeCount":96},[],{"trials":1755,"activeCount":96},[],{"trials":1757,"activeCount":96},[],{"trials":1759,"activeCount":96},[],{"intervention":1761,"totalTrials":166,"cells":1762},"oral vinorelbine",{"EARLY_PHASE1":1763,"PHASE1":1765,"PHASE2":1778,"PHASE3":1780,"PHASE4":1782,"NA":1784},{"trials":1764,"activeCount":96},[],{"trials":1766,"activeCount":96},[1767],{"nctId":1768,"briefTitle":1769,"status":146,"phases":1770,"primaryCompletion":1771,"completion":1772,"start":1773,"enrollment":1774,"conditions":1775,"interventions":1776},"NCT00870532","Study of Combination of Metronomic Oral Vinorelbine and Sorafenib in Patients With Advanced Non-small Cell Lung Cancer",[85],"2013-08","2013-09","2008-06",52,[28],[1761,1777],"sorafenib",{"trials":1779,"activeCount":96},[],{"trials":1781,"activeCount":96},[],{"trials":1783,"activeCount":96},[],{"trials":1785,"activeCount":96},[],{"intervention":1777,"totalTrials":166,"cells":1787},{"EARLY_PHASE1":1788,"PHASE1":1790,"PHASE2":1796,"PHASE3":1798,"PHASE4":1800,"NA":1802},{"trials":1789,"activeCount":96},[],{"trials":1791,"activeCount":96},[1792],{"nctId":1768,"briefTitle":1769,"status":146,"phases":1793,"primaryCompletion":1771,"completion":1772,"start":1773,"enrollment":1774,"conditions":1794,"interventions":1795},[85],[28],[1761,1777],{"trials":1797,"activeCount":96},[],{"trials":1799,"activeCount":96},[],{"trials":1801,"activeCount":96},[],{"trials":1803,"activeCount":96},[],{"intervention":1805,"totalTrials":166,"cells":1806},"Afatinib",{"EARLY_PHASE1":1807,"PHASE1":1809,"PHASE2":1821,"PHASE3":1823,"PHASE4":1825,"NA":1827},{"trials":1808,"activeCount":96},[],{"trials":1810,"activeCount":96},[1811],{"nctId":1812,"briefTitle":1813,"status":104,"phases":1814,"primaryCompletion":1815,"completion":1815,"start":1816,"enrollment":590,"conditions":1817,"interventions":1820},"NCT03711422","Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC",[85],"2019-12-20","2018-11-16",[30,1818,1819],"Leptomeningeal Disease","Central Nervous System Metastases",[1805,1805],{"trials":1822,"activeCount":96},[],{"trials":1824,"activeCount":96},[],{"trials":1826,"activeCount":96},[],{"trials":1828,"activeCount":96},[],{"intervention":1830,"totalTrials":166,"cells":1831},"LBH589 and RAD001",{"EARLY_PHASE1":1832,"PHASE1":1834,"PHASE2":1847,"PHASE3":1849,"PHASE4":1851,"NA":1853},{"trials":1833,"activeCount":96},[],{"trials":1835,"activeCount":96},[1836],{"nctId":1837,"briefTitle":1838,"status":115,"phases":1839,"primaryCompletion":1840,"completion":1841,"start":1842,"enrollment":1843,"conditions":1844,"interventions":1846},"NCT01341834","Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors",[85],"2016-06","2018-12","2010-03",49,[1845],"Nasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour",[1830],{"trials":1848,"activeCount":96},[],{"trials":1850,"activeCount":96},[],{"trials":1852,"activeCount":96},[],{"trials":1854,"activeCount":96},[],{"intervention":1856,"totalTrials":166,"cells":1857},"Trametinib",{"EARLY_PHASE1":1858,"PHASE1":1860,"PHASE2":1874,"PHASE3":1876,"PHASE4":1878,"NA":1880},{"trials":1859,"activeCount":96},[],{"trials":1861,"activeCount":96},[1862],{"nctId":1863,"briefTitle":1864,"status":115,"phases":1865,"primaryCompletion":1866,"completion":1867,"start":1868,"enrollment":1869,"conditions":1870,"interventions":1872},"NCT04303403","Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma",[85],"2023-06-30","2024-03-31","2018-07-31",48,[23,1871],"Pancreatic Adenocarcinoma",[1856,1873],"Ruxolitinib",{"trials":1875,"activeCount":96},[],{"trials":1877,"activeCount":96},[],{"trials":1879,"activeCount":96},[],{"trials":1881,"activeCount":96},[],{"intervention":1873,"totalTrials":166,"cells":1883},{"EARLY_PHASE1":1884,"PHASE1":1886,"PHASE2":1892,"PHASE3":1894,"PHASE4":1896,"NA":1898},{"trials":1885,"activeCount":96},[],{"trials":1887,"activeCount":96},[1888],{"nctId":1863,"briefTitle":1864,"status":115,"phases":1889,"primaryCompletion":1866,"completion":1867,"start":1868,"enrollment":1869,"conditions":1890,"interventions":1891},[85],[23,1871],[1856,1873],{"trials":1893,"activeCount":96},[],{"trials":1895,"activeCount":96},[],{"trials":1897,"activeCount":96},[],{"trials":1899,"activeCount":96},[],{"intervention":1901,"totalTrials":166,"cells":1902},"IV Nivolumab",{"EARLY_PHASE1":1903,"PHASE1":1905,"PHASE2":1921,"PHASE3":1923,"PHASE4":1925,"NA":1927},{"trials":1904,"activeCount":96},[],{"trials":1906,"activeCount":96},[1907],{"nctId":1908,"briefTitle":1909,"status":1910,"phases":1911,"primaryCompletion":1912,"completion":1912,"start":1913,"enrollment":96,"conditions":1914,"interventions":1916},"NCT04230330","Nivolumab in Combination With GDP\u002F L-asparaginase in NK\u002F T-cell Lymphoma","WITHDRAWN",[85],"2020-06-12","2019-12-12",[1915],"NK\u002FT Cell Lymphoma",[1901,1901,1917,1918,1919,1920],"IV Gemcitabine","IV Cisplatin","IV\u002FPO Dexamethasone","IV L-asparaginase",{"trials":1922,"activeCount":96},[],{"trials":1924,"activeCount":96},[],{"trials":1926,"activeCount":96},[],{"trials":1928,"activeCount":96},[],{"intervention":1917,"totalTrials":166,"cells":1930},{"EARLY_PHASE1":1931,"PHASE1":1933,"PHASE2":1939,"PHASE3":1941,"PHASE4":1943,"NA":1945},{"trials":1932,"activeCount":96},[],{"trials":1934,"activeCount":96},[1935],{"nctId":1908,"briefTitle":1909,"status":1910,"phases":1936,"primaryCompletion":1912,"completion":1912,"start":1913,"enrollment":96,"conditions":1937,"interventions":1938},[85],[1915],[1901,1901,1917,1918,1919,1920],{"trials":1940,"activeCount":96},[],{"trials":1942,"activeCount":96},[],{"trials":1944,"activeCount":96},[],{"trials":1946,"activeCount":96},[],{"intervention":1918,"totalTrials":166,"cells":1948},{"EARLY_PHASE1":1949,"PHASE1":1951,"PHASE2":1957,"PHASE3":1959,"PHASE4":1961,"NA":1963},{"trials":1950,"activeCount":96},[],{"trials":1952,"activeCount":96},[1953],{"nctId":1908,"briefTitle":1909,"status":1910,"phases":1954,"primaryCompletion":1912,"completion":1912,"start":1913,"enrollment":96,"conditions":1955,"interventions":1956},[85],[1915],[1901,1901,1917,1918,1919,1920],{"trials":1958,"activeCount":96},[],{"trials":1960,"activeCount":96},[],{"trials":1962,"activeCount":96},[],{"trials":1964,"activeCount":96},[],{"intervention":1919,"totalTrials":166,"cells":1966},{"EARLY_PHASE1":1967,"PHASE1":1969,"PHASE2":1975,"PHASE3":1977,"PHASE4":1979,"NA":1981},{"trials":1968,"activeCount":96},[],{"trials":1970,"activeCount":96},[1971],{"nctId":1908,"briefTitle":1909,"status":1910,"phases":1972,"primaryCompletion":1912,"completion":1912,"start":1913,"enrollment":96,"conditions":1973,"interventions":1974},[85],[1915],[1901,1901,1917,1918,1919,1920],{"trials":1976,"activeCount":96},[],{"trials":1978,"activeCount":96},[],{"trials":1980,"activeCount":96},[],{"trials":1982,"activeCount":96},[],{"intervention":1920,"totalTrials":166,"cells":1984},{"EARLY_PHASE1":1985,"PHASE1":1987,"PHASE2":1993,"PHASE3":1995,"PHASE4":1997,"NA":1999},{"trials":1986,"activeCount":96},[],{"trials":1988,"activeCount":96},[1989],{"nctId":1908,"briefTitle":1909,"status":1910,"phases":1990,"primaryCompletion":1912,"completion":1912,"start":1913,"enrollment":96,"conditions":1991,"interventions":1992},[85],[1915],[1901,1901,1917,1918,1919,1920],{"trials":1994,"activeCount":96},[],{"trials":1996,"activeCount":96},[],{"trials":1998,"activeCount":96},[],{"trials":2000,"activeCount":96},[],{"intervention":2002,"totalTrials":166,"cells":2003},"irinotecan hydrochloride",{"EARLY_PHASE1":2004,"PHASE1":2006,"PHASE2":2019,"PHASE3":2021,"PHASE4":2023,"NA":2025},{"trials":2005,"activeCount":96},[],{"trials":2007,"activeCount":96},[2008],{"nctId":2009,"briefTitle":2010,"status":146,"phases":2011,"primaryCompletion":2012,"completion":2013,"start":2014,"enrollment":2015,"conditions":2016,"interventions":2018},"NCT00731276","Irinotecan in Treating Asian Patients With Solid Tumors",[85],"2015-11","2016-04","2008-04-03",18,[2017],"Unspecified Adult Solid Tumor, Protocol Specific",[2002],{"trials":2020,"activeCount":96},[],{"trials":2022,"activeCount":96},[],{"trials":2024,"activeCount":96},[],{"trials":2026,"activeCount":96},[],{"intervention":2028,"totalTrials":166,"cells":2029},"Rapamycin",{"EARLY_PHASE1":2030,"PHASE1":2032,"PHASE2":2044,"PHASE3":2046,"PHASE4":2048,"NA":2050},{"trials":2031,"activeCount":96},[],{"trials":2033,"activeCount":96},[2034],{"nctId":2035,"briefTitle":2036,"status":146,"phases":2037,"primaryCompletion":2038,"start":2039,"enrollment":2040,"conditions":2041,"interventions":2042},"NCT00467194","Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery",[85],"2011-05","2006-12",27,[531],[2028,2043],"Bevacizumab",{"trials":2045,"activeCount":96},[],{"trials":2047,"activeCount":96},[],{"trials":2049,"activeCount":96},[],{"trials":2051,"activeCount":96},[],{"intervention":2043,"totalTrials":166,"cells":2053},{"EARLY_PHASE1":2054,"PHASE1":2056,"PHASE2":2062,"PHASE3":2064,"PHASE4":2066,"NA":2068},{"trials":2055,"activeCount":96},[],{"trials":2057,"activeCount":96},[2058],{"nctId":2035,"briefTitle":2036,"status":146,"phases":2059,"primaryCompletion":2038,"start":2039,"enrollment":2040,"conditions":2060,"interventions":2061},[85],[531],[2028,2043],{"trials":2063,"activeCount":96},[],{"trials":2065,"activeCount":96},[],{"trials":2067,"activeCount":96},[],{"trials":2069,"activeCount":96},[],{"intervention":2071,"totalTrials":166,"cells":2072},"Drug treatment",{"EARLY_PHASE1":2073,"PHASE1":2075,"PHASE2":2077,"PHASE3":2079,"PHASE4":2081,"NA":2083},{"trials":2074,"activeCount":96},[],{"trials":2076,"activeCount":96},[],{"trials":2078,"activeCount":96},[],{"trials":2080,"activeCount":96},[],{"trials":2082,"activeCount":96},[],{"trials":2084,"activeCount":96},[2085],{"nctId":2086,"briefTitle":2087,"status":146,"phases":2088,"primaryCompletion":2089,"completion":503,"start":2090,"enrollment":1023,"conditions":2091,"interventions":2092},"NCT04451603","LiverMultiScan Analysis of MRI Scans in HCC",[],"2021-03-16","2018-10-19",[18],[2071],{"intervention":2094,"totalTrials":166,"cells":2095},"Doxorubicin",{"EARLY_PHASE1":2096,"PHASE1":2098,"PHASE2":2100,"PHASE3":2102,"PHASE4":2104,"NA":2106},{"trials":2097,"activeCount":96},[],{"trials":2099,"activeCount":96},[],{"trials":2101,"activeCount":96},[],{"trials":2103,"activeCount":96},[],{"trials":2105,"activeCount":96},[],{"trials":2107,"activeCount":96},[2108],{"nctId":2109,"briefTitle":2110,"status":115,"phases":2111,"primaryCompletion":2112,"completion":1867,"start":2113,"enrollment":26,"conditions":2114,"interventions":2116},"NCT03792867","Radical Resection and HIPEC for Recurrent Retroperitoneal Sarcoma",[89],"2022-02-28","2018-07-23",[2115],"Retroperitoneal Sarcoma",[2094]]